We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Immunoassay Developed for Rapid Leptospirosis Diagnosis

By LabMedica International staff writers
Posted on 13 Nov 2012
A rapid assay has been developed using immunodominant Leptospira immunoglobulin-like proteins in a Dual Path Platform (DPP) for the diagnosis of leptospirosis.

The rapid point-of-care immunoassay was evaluated for accuracy in diagnostic performance and compared with the microscopic agglutination test (MAT), in an urban setting.

Scientists at Duke University School of Medicine (Durham, NC, USA) and their collaborators measured the sensitivity of the assay using 446 serum samples from 378 individuals with either mild or severe leptospirosis from two urban Brazilian populations. Control sera, including healthy blood donors, dengue cases, and patients with confirmed syphilis were also tested.

The DPP assay for leptospirosis was developed by Chembio Diagnostic Systems (Medford, NY, USA) and is manufactured by Bio-Manguinhos (Rio de Janeiro, Brazil). The sera assayed by the DPP were also tested by an immunoglobulin M enzyme-linked immunosorbent assay (IgM- ELISA) and the MAT. Three independent operators visually interpreted results of the DPP after 20 minutes as either positive or negative.

The overall sensitivity for paired sera was 100% for severe and 73% for mild disease. In the acute phase of the infection, the assay achieved a sensitivity of 85% for severe and 64% for mild leptospirosis. Within seven days of illness onset, the assay achieved a sensitivity of 77% for severe disease and 60% for mild leptospirosis. Sensitivity of the DPP assay was similar to that for IgM-ELISA and increased with both duration of symptoms.

The authors concluded that the DPP assay performed acceptably well for diagnosis of severe acute clinical leptospirosis and can be easily implemented in hospitals and health posts where leptospirosis is a major public health problem. However, test accuracy may need improvement for mild disease and early stage leptospirosis, particularly in regions with high transmission. The study was published on November 1, 2012, in the journal Public Library of Science Neglected Tropical Diseases (PLoSNTD).

Related Links:

Duke University School of Medicine
Chembio Diagnostic Systems
Bio-Manguinhos


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
Rapid Molecular Testing Device
FlashDetect Flash10

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more